PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 1177: Prognostic implications of circulating Hepsin in prostate cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTaylor D. WadleyACAdam ColeBJBlake Johnson

Discussion

Loading...

Member takes

Overview

Prognostic analysis reveals circulating Hepsin identifies risk of biochemical recurrence in prostate cancer, indicating its clinical relevance.

Key Points

  • This research aims to assess the clinical relevance of circulating Hepsin as a biomarker for prostate cancer progression and outcomes.
  • Developed a quantitative sandwich ELISA for detecting circulating Hepsin.
  • Conducted retrospective analyses of 543 patients undergoing prostate evaluation.
  • Assessed clinicopathologic variables between Hepsin-positive and -negative groups.
  • Analyzed biochemical recurrence-free survival among RALP patients using Kaplan-Meier and Cox regression.
  • Circulating Hepsin positivity was found in 20% of patients.
  • Hepsin-positive patients had significantly higher cancer incidence, advanced stage, and metastasis compared to Hepsin-negative patients.
  • Kaplan-Meier analysis indicated reduced recurrence-free survival with Hepsin positivity (log-rank p < 0.001).
  • Circulating Hepsin is an independent predictor of biochemical recurrence (p = 0.0001).
  • Hepsin positivity adds prognostic value in high CAPRA-S score patients.

Cite This Study

Wadley et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd62a79560c99a0a36aahttps://doi.org/10.1158/1538-7445.am2026-1177
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2546: An alternative screening method for prostate cancer to serum prostate specific antigen2026
  2. 2Abstract 1066: Early detection of prostate carcinoma using trajectories of circulating epithelial tumor cell (CETCs/CTCs) numbers2026
  3. 3Abstract 3353: The emerging role of extracellular HSP90 in prostate cancer progression to a metastatic phenotype2024
  4. 4Circulating Hsp70 Reflects Tumor Burden and Stage-Dependent Disease Progression Across Multiple Solid Tumor Entities2026
  5. 5Predicting surgical efficacy and diagnosing histological inflammation: the clinical significance of prostate exosome proteins in benign prostatic hyperplasia2024